Warning! GuruFocus detected
5 Severe warning signs
with A89.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Adocia
NAICS : 325412
ISIN : FR0011184241
Compare
Compare
Traded in other countries / regions
ADOC.FranceA89.Germany0QAI.UKADOIF.USA IPO Date
2013-10-16Description
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.78 | |||||
| Equity-to-Asset | -0.33 | |||||
| Debt-to-Equity | -1.72 | |||||
| Debt-to-EBITDA | -0.68 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.55 | |||||
| Beneish M-Score | -4.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17 | |||||
| 3-Year EBITDA Growth Rate | 15.3 | |||||
| 3-Year EPS without NRI Growth Rate | 22.9 | |||||
| 3-Year FCF Growth Rate | 47.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 161.83 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.32 | |||||
| 9-Day RSI | 18.83 | |||||
| 14-Day RSI | 23.77 | |||||
| 3-1 Month Momentum % | -20.97 | |||||
| 6-1 Month Momentum % | -5.25 | |||||
| 12-1 Month Momentum % | -43.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.92 | |||||
| Quick Ratio | 0.89 | |||||
| Cash Ratio | 0.5 | |||||
| Days Inventory | 64.17 | |||||
| Days Sales Outstanding | 103.06 | |||||
| Days Payable | 1484.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.3 | |||||
| Shareholder Yield % | 15.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.42 | |||||
| Operating Margin % | -2909.94 | |||||
| Net Margin % | -3960.8 | |||||
| FCF Margin % | -2321.41 | |||||
| ROA % | -89.27 | |||||
| ROIC % | -66.67 | |||||
| 3-Year ROIIC % | 133.94 | |||||
| ROC (Joel Greenblatt) % | -657.03 | |||||
| ROCE % | -4268.15 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 0.75 | |||||
| PS Ratio | 84.75 | |||||
| EV-to-EBIT | -3.19 | |||||
| EV-to-EBITDA | -3.28 | |||||
| EV-to-Revenue | 122.63 | |||||
| EV-to-Forward-Revenue | 0.6 | |||||
| EV-to-FCF | -5.28 | |||||
| Price-to-GF-Value | 0.7 | |||||
| Price-to-Median-PS-Value | 1.48 | |||||
| Earnings Yield (Greenblatt) % | -31.35 | |||||
| FCF Yield % | -19.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adocia Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.523 | ||
| EPS (TTM) (€) | -1.5 | ||
| Beta | -0.21 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.63 | ||
| Volatility % | 79.62 | ||
| 14-Day RSI | 23.77 | ||
| 14-Day ATR (€) | 0.201916 | ||
| 20-Day SMA (€) | 4.17275 | ||
| 12-1 Month Momentum % | -43.89 | ||
| 52-Week Range (€) | 3.28 - 10.54 | ||
| Shares Outstanding (Mil) | 18.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adocia Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adocia Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adocia Frequently Asked Questions
What is Adocia(STU:A89)'s stock price today?
The current price of STU:A89 is €3.28. The 52 week high of STU:A89 is €10.54 and 52 week low is €3.28.
When is next earnings date of Adocia(STU:A89)?
The next earnings date of Adocia(STU:A89) is .
Does Adocia(STU:A89) pay dividends? If so, how much?
Adocia(STU:A89) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers